Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Thursday, May 8, 2014

Teva Announces COPAXONE® Recognized as “Brand of the Year” by Pharmaceutical Executive Magazine

Teva Announces COPAXONE® Recognized as “Brand of the Year” by Pharmaceutical Executive Magazine

JERUSALEM--(BUSINESS WIRE)--Thu, May 8, 2014,
Teva Pharmaceutical Industries Ltd., (TEVA) today announced that COPAXONE® (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 “Brand of The Year” by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry.
“Teva and the COPAXONE® team are honored to be acknowledged by Pharmaceutical Executive, a respected voice in our industry,” said Mike Derkacz, Vice President, and General Manager of Teva CNS. “The award is a tribute to the hard work of Teva employees and scientists throughout the years; the growth of COPAXONE® and the loyalty of prescribers and patients alike; and speaks to the product’s benefits, tolerability and safety."
The “Brand of The Year” award was received on behalf of Teva by John Hassler, Vice President of Marketing for Teva CNS at an award ceremony hosted by Pharmaceutical Executive in New York. “For more than 20 years, Teva has consistently focused on making this brand an appropriate choice for many patients with relapsing forms of multiple sclerosis with rigorous clinical studies, product enhancements and patient support services like Shared Solutions®. Our most recent and significant product development is the new FDA approved, three-times-a-week dose of COPAXONE® 40mg. This honor is a testament to that work,” he said.
COPAXONE® was first approved for marketing by the U.S. FDA as a treatment for relapsing-remitting multiple sclerosis in 1996. Daily COPAXONE® 20 mg/mL is approved in more than 50 countries worldwide, including the United States, all European countries, Israel, Canada, Mexico, Australia and Russia.
On January 28, 2014, Teva announced that the U.S. Food and Drug Administration approved the Company’s supplemental new drug application (sNDA) for three-times-a-week COPAXONE® 40 mg/mL, a new dose of COPAXONE®. This new formulation allows for a less-frequent subcutaneous dosing regimen as compared to the COPAXONE® 20 mg/mL daily dose option.
About COPAXONE®

……..


To comment - click the comment link shown below
…….
Share our Articles with others
……
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information
 -------------
Donate Now Please - Click here
Thank you    
…………………….
.

No comments: